Madrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says

MT Newswires Live

Feb 28, 2025

Madrigal Pharmaceuticals' (MDGL) shares remain undervalued given the company's long-term potential opportunity from its Rezdiffra MASH business, UBS said Thursday in a note.

The firm's upbeat outlook comes a day after the company said patients with metabolic dysfunction-associated steatohepatitis, or MASH, treated with its Rezdiffra drug showed "marked reductions" in liver stiffness.

UBS said the Rezdiffra launch is expected to accelerate significantly in 2025, supported by robust demand and manageable competition.

The firm sees potential for outperformance relative to consensus estimates for the the company this year as "strong MASH launches" should continue.

UBS reiterates its buy rating on the stock with a $441 price target.

Price: 349.03, Change: -6.85, Percent Change: -1.92

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2514333530"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514333530\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514333530?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 01:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514333530","market":"nz","top_or_hot":-1,"title":"Madrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says","media":"MT Newswires Live","content":"<html><body><p> Madrigal Pharmaceuticals' (MDGL) shares remain undervalued given the company's long-term potential opportunity from its Rezdiffra MASH business, UBS said Thursday in a note.</p><p>The firm's upbeat outlook comes a day after the company said patients with metabolic dysfunction-associated steatohepatitis, or MASH, treated with its Rezdiffra drug showed \"marked reductions\" in liver stiffness.</p><p>UBS said the Rezdiffra launch is expected to accelerate significantly in 2025, supported by robust demand and manageable competition.</p><p>The firm sees potential for outperformance relative to consensus estimates for the the company this year as \"strong MASH launches\" should continue.</p><p>UBS reiterates its buy rating on the stock with a $441 price target.</p><p>Price: 349.03, Change: -6.85, Percent Change: -1.92</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Madrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMadrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-28 01:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Madrigal Pharmaceuticals' (MDGL) shares remain undervalued given the company's long-term potential opportunity from its Rezdiffra MASH business, UBS said Thursday in a note.</p><p>The firm's upbeat outlook comes a day after the company said patients with metabolic dysfunction-associated steatohepatitis, or MASH, treated with its Rezdiffra drug showed \"marked reductions\" in liver stiffness.</p><p>UBS said the Rezdiffra launch is expected to accelerate significantly in 2025, supported by robust demand and manageable competition.</p><p>The firm sees potential for outperformance relative to consensus estimates for the the company this year as \"strong MASH launches\" should continue.</p><p>UBS reiterates its buy rating on the stock with a $441 price target.</p><p>Price: 349.03, Change: -6.85, Percent Change: -1.92</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDGL","symbol_name":"Madrigal Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2514333530","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514333530","pubTimestamp":1740677764,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Madrigal Pharmaceuticals'  shares remain undervalued given the company's long-term potential opportunity from its Rezdiffra MASH business, UBS said Thursday in a note.The firm's upbeat outlook comes a day after the company said patients with metabolic dysfunction-associated steatohepatitis, or MASH, treated with its Rezdiffra drug showed \"marked reductions\" in liver stiffness.UBS said the Rezdiffra launch is expected to accelerate significantly in 2025, supported by robust demand and manageable competition.The firm sees potential for outperformance relative to consensus estimates for the the company this year as \"strong MASH launches\" should continue.UBS reiterates its buy rating on the stock with a $441 price target.Price: 349.03, Change: -6.85, Percent Change: -1.92","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDGL":"Madrigal Pharmaceuticals, Inc.","BK4139":"生物科技","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"translate_title":"瑞银表示，Madrigal Pharmaceuticals股价在长期增长潜力中仍被低估","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1},"content_text":"Madrigal Pharmaceuticals' (MDGL) shares remain undervalued given the company's long-term potential opportunity from its Rezdiffra MASH business, UBS said Thursday in a note.The firm's upbeat outlook comes a day after the company said patients with metabolic dysfunction-associated steatohepatitis, or MASH, treated with its Rezdiffra drug showed \"marked reductions\" in liver stiffness.UBS said the Rezdiffra launch is expected to accelerate significantly in 2025, supported by robust demand and manageable competition.The firm sees potential for outperformance relative to consensus estimates for the the company this year as \"strong MASH launches\" should continue.UBS reiterates its buy rating on the stock with a $441 price target.Price: 349.03, Change: -6.85, Percent Change: -1.92","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}